Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)

Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)

Background To compare survival outcomes of patients with advanced or metastatic non‐small cell lung cancer (NSCLC) who received immunotherapy as first‐, second‐ or beyond line, versus matched patients receiving standard chemotherapy with special characterization of hyperprogressors. Methods A retros...

Full description

Bibliographic Details
Main Authors: Alejandro Ruiz‐Patiño, Oscar Arrieta, Andrés F. Cardona, Claudio Martín, Luis E. Raez, Zyanya L. Zatarain‐Barrón, Feliciano Barrón, Luisa Ricaurte, María A. Bravo‐Garzón, Luis Mas, Luis Corrales, Leonardo Rojas, Lorena Lupinacci, Florencia Perazzo, Carlos Bas, Omar Carranza, Carmen Puparelli, Manglio Rizzo, Rossana Ruiz, Christian Rolfo, Pilar Archila, July Rodríguez, Carolina Sotelo, Carlos Vargas, Hernán Carranza, Jorge Otero, Luis E. Pino, Carlos Ortíz, Paola Laguado, Rafael Rosell, on behalf of the CLICaP
Format: Article
Language:English
Published: Wiley 2020-02-01
Series:Thoracic Cancer
Subjects:
Adult
immunotherapy
lung neoplasms
neoplasms/drug therapy
programmed cell death 1 receptor/antagonists & inhibitors
Online Access:https://doi.org/10.1111/1759-7714.13272

Internet

https://doi.org/10.1111/1759-7714.13272

Similar Items